Although we found that a higher percentage of MS patients had abnormal Anti‐TG (8.2%) and abnormal Anti‐TPO (16.4%) compared to the control group, difference among groups did not meet standard statistical significance (see Table 1). This evidence concerns the gene TPO and myeloid sarcoma.